Provided by Tiger Trade Technology Pte. Ltd.

Ocular Therapeutix

10.79
-0.2950-2.66%
Volume:239.58K
Turnover:2.59M
Market Cap:2.36B
PE:-7.63
High:11.05
Open:11.01
Low:10.73
Close:11.08
52wk High:16.44
52wk Low:6.23
Shares:218.91M
Float Shares:185.00M
Volume Ratio:0.28
T/O Rate:0.13%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.4140
EPS(LYR):-1.4203
ROE:-72.99%
ROA:-34.95%
PB:4.54
PE(LYR):-7.59

Loading ...

Assessing Ocular Therapeutix (OCUL) Valuation After Recent Share Price Weakness

Simply Wall St.
·
Jun 08

BRIEF-Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Reuters
·
Jun 05

Ocular Therapeutix grants inducement awards of options for 51,775 shares, RSUs for 16,950 shares to new hires

Reuters
·
Jun 05

Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Jun 05

Ocular Therapeutix™ to Participate in Clinical Trials at the Summit 2026

GlobeNewswire
·
Jun 04

Ocular Therapeutix to host investor day with retinal disease experts

Reuters
·
Jun 02

Ocular Therapeutix™ to Host Investor Day on June 17, 2026

GlobeNewswire
·
Jun 02

Ocular Therapeutix Insiders Make a Wave of High-Level Stock Moves

TIPRANKS
·
May 29

Can Ocular Therapeutix's (OCUL) Rising Losses on Flat Revenue Still Support Its R&D Ambitions?

Simply Wall St.
·
May 20

Ocular Therapeutix grants new HR chief options for 75,000 shares, 25,000 RSUs

Reuters
·
May 15

Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
May 15

Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
May 15

EyePoint's late-stage eye drug trials to continue after safety panel review

Reuters
·
May 14

A Look At Ocular Therapeutix (OCUL) Valuation After Recent Share Price Pullback

Simply Wall St.
·
May 13

BRIEF-Ocular Therapeutix reports inducement grants under Nasdaq listing rule 5635(C)(4)

Reuters
·
May 09

Ocular Therapeutix grants 12 new hires options for 127,650 shares, RSUs for 41,550 shares

Reuters
·
May 09

Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
May 09

Ocular Therapeutix Advances FDA Talks on Single-Trial Filing for Eye Drug, RBC Says

MT Newswires Live
·
May 07

Ocular Therapeutix Price Target Maintained With a $30.00/Share by RBC Capital

Dow Jones
·
May 06

Ocular Therapeutix (OCUL) Gets a Buy from Chardan Capital

TIPRANKS
·
May 06